Vertex Pharmaceuticals
NEWS
The effort was announced last week by the Henri A. Termeer Tribute Committee.
These stocks have been given a Strong Buy or Buy rating by 80% or more brokers.
The analyst identified Vertex and Alexion as his top two picks among large cap biotechs in 2018.
It was a pretty good year for the stock market, but how about for biotech stocks?
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
Keith Speights, writing for The Motley Fool, notes one biotech that’s booming.
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results.
Vertex has done everything an investor could ask for in 2017, including double its market cap to almost $40B.
JOBS
IN THE PRESS